Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07148323 · ClinicalTrials.gov registry record

HemoSphere Alta Study

A clinical trial of Hemodynamic Instability, sponsored by Edwards Lifesciences.

Recruiting
Registry status
100
Enrollment target
1
Study location

NCT07148323 is a study of Hemodynamic Instability that is actively recruiting participants, run by Edwards Lifesciences. The registered enrollment target is 100 participants, below the 6,285-participant average among 5 other Hemodynamic Instability trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07148323, a study of Hemodynamic Instability, is actively recruiting participants, sponsored by Edwards Lifesciences.

RECRUITING
Registry status
100 participants
Enrollment target
1
Study location

Study Summary

A prospective, non-randomized single arm study using the HemoSphere Alta Advanced Monitoring Platform and associated devices in adult subjects. Data collected from enrolled study subjects will be used for continual device development purposes.

Conditions Studied

Interventions

  • DEVICE HemoSphere Alta Monitor, Swan-Ganz IQ pulmonary arterial catheter, ForeSight IQ Large sensor, and Acumen IQ sensor

Study Locations (1)

New York

  • University of Rochester Medical Center - Rochester

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-10-14
Est. Completion 2026-12

Sponsor

Edwards Lifesciences

57 total trials

What the Registry Record Tells You About NCT07148323

The ClinicalTrials.gov registry entry for NCT07148323 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,285-participant average among 5 other Hemodynamic Instability trials with a reported enrollment target (98% lower). The listed sponsor is Edwards Lifesciences, which has 57 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hemodynamic Instability appearing as the primary indexed condition, and to 1 intervention - of which HemoSphere Alta Monitor, Swan-Ganz IQ pulmonary arterial catheter, ForeSight IQ Large sensor, and Acumen IQ sensor is the first listed.

NCT07148323 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT07148323 about?

NCT07148323 is a clinical study titled "HemoSphere Alta Study". A prospective, non-randomized single arm study using the HemoSphere Alta Advanced Monitoring Platform and associated devices in adult subjects. Data collected from enrolled study subjects will be used for continual device development purposes.

What is the current status of trial NCT07148323?

This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2025-10-14. Estimated completion is 2026-12.

What conditions does trial NCT07148323 study?

This clinical trial studies the following conditions: Hemodynamic Instability.

What interventions are being tested in trial NCT07148323?

The interventions under investigation include: HemoSphere Alta Monitor, Swan-Ganz IQ pulmonary arterial catheter, ForeSight IQ Large sensor, and Acumen IQ sensor (DEVICE).

Who is sponsoring clinical trial NCT07148323?

This trial is sponsored by Edwards Lifesciences, which has 57 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07148323 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hemodynamic Instability

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.